[1]苏 志,吴 蔚,吴智钢,等.含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效观察[J].医学信息,2018,31(21):83-86.[doi:10.3969/j.issn.1006-1959.2018.21.022]
　SU Zhi,WU Wei,WU Zhi-gang,et al.Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for OsteosarcomaC[J].Journal of Medical Information,2018,31(21):83-86.[doi:10.3969/j.issn.1006-1959.2018.21.022]
点击复制

含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年21期
页码:
83-86
栏目:
论著
出版日期:
2018-11-01

文章信息/Info

Title:
Clinical Efficacy of Neoadjuvant Chemotherapy with Lobaplatin Combined with Limb Salvage Surgery for OsteosarcomaC
文章编号:
1006-1959（2018）21-0083-04
作者:
苏 志1; 吴 蔚2; 吴智钢1; 权 冬1; 辛 忍1; 王建功1; 聂林洋1
1.解放军第五一八医院骨科，陕西 西安 710043；2.解放军65547部队卫生连，辽宁 鞍山 114200
Author(s):
SU Zhi1; WU Wei2; WU Zhi-gang1; QUAN Dong1; XIN Ren1; WANG Jian-gong1; NIE Lin-yang1
1.Department of Orthopedics,PLA 518th Hospital, Xi 'an 710043 ,Shaanxi,China;2. PLA 65547 Army Medical Company,Anshan 114200,Liaoning,ChinaC
关键词:
洛铂; 新辅助化疗; 保肢手术; 骨肉瘤
Keywords:
Lobaplatin; Neoadjuvant chemotherapy; Limb salvage surgery; Osteosarcoma
分类号:
R738.1
DOI:
10.3969/j.issn.1006-1959.2018.21.022
文献标志码:
A
摘要:
目的 探讨含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤的临床疗效。方法 选取我院2013年5月~2017年5月收治的120例骨肉瘤患者作为研究对象，采用随机数字表法分为观察组和对照组，各60例。观察组患者采用含洛铂的新辅助动脉灌注化疗联合保肢手术及术后辅助化疗治疗，对照组患者采用传统保肢手术联合术后化疗，分别从近期临床化疗临床效果、化疗不良反应（胃肠道反应、白细胞下降、末梢神经毒性、血小板减少、发热、肾功能损害、肝功能损害、骨髓抑制等）比较两组患者近期临床疗效；从肢体功能Enneking评分及优良率比较两组患者远期临床疗效。结果 观察组患者近期临床化疗总有效率95.00%，远高于对照组患者的75.00%（P＜0.05）；且观察组不良反应发生率仅为 16.67%，远低于对照组的35.00%（P＜0.05）；观察组患者Enneking评分为（26.11±2.37）分，高于对照组（24.52±3.69）分；且观察组优良率为83.33%，高于对照组的60.00%（P＜0.05）。结论 含洛铂方案新辅助化疗结合保肢手术治疗骨肉瘤具有良好的近远期临床疗效。
Abstract:
Objective To explore the clinical efficacy of neoadjuvant chemotherapy with losplatin combined with limb salvage in the treatment of osteosarcoma.Methods From May 2013 to May 2017 treated 120 cases of patients with osteosarcoma as the research object, were randomly divided into observation group （n=60） and control group （n=60）,the patients in the observation group were treated with neoadjuvant arterial infusion chemotherapy containing loplatin combined with limb salvage surgery and postoperative adjuvant chemotherapy, while the patients in the control group were treated with traditional limb salvage surgery combined with postoperative chemotherapy. Side effects of chemotherapy (gastrointestinal reaction, leukopenia, peripheral neurotoxicity, thrombocytopenia, fever, renal function damage, liver function damage, bone marrow depression, etc.) were compared between the two groups. To compare the long-term clinical effect of the two groups from limb function Enneking score and excellent and good rate.Results The short-term clinical efficacy data showed that the total effective rate of clinical chemotherapy in the observation group was 95.00%, which was much higher than 75.00% of the control group （P<0.05）.The incidence of adverse reactions in the observation group was only 16.67%, which was much lower than 35.00% in the control group （P<0.05）. The Enneking score of the observation group was (26.11±2.37), which was higher than that of the control group (24.52±3.69). The excellent and good rate of the observation group was 83.33%, which was higher than that of the control group 60.00% (P<0.05). Conclusion Neoadjuvant chemotherapy with lobaplatin combined with limb salvage surgery for osteosarcoma has a good near-term clinical effect.Conclusion Neoadjuvant chemotherapy with loroplatin-containing regimen combined with limb salvage surgery has good short-term and long-term clinical efficacy in the treatment of osteosarcoma.

参考文献/References:

[1]朱皓东,吴智钢,王臻,等.含洛铂方案的新辅助化疗在骨肉瘤及尤因肉瘤中的疗效观察[J].中华骨与关节外科杂志,2013,2(3):225-229. [2]卢贤哲,唐毓金.含洛铂动脉灌注化疗联合保肢手术治疗肢体骨肉瘤的近远期临床疗效及其对Ras、ErbB3和PTEN含量的影响[J].实用药物与临床,2016,19(5):553-557. [3]吴智钢,王臻,郭征,等.洛铂在骨肉瘤及PNET新辅助化疗中的疗效观察[C]//中国西部肿瘤学术大会.2013. [4]费菲,曲莉莉.牛晓辉:肢体经典型骨肉瘤循证临床诊疗指南.中国医师协会骨科医师分会《骨肿瘤循证临床诊疗指南》编委会成员权威解读[J].中国医药科学,2015,5(12):1-3. [5]余强,杨浩森,王彦川,等.新辅助化疗联合保肢手术治疗骨肉瘤的疗效[J].医学研究杂志, 2016,45 (4):134-137. [6]陈国景,王臻,叶新红,等.洛铂联合阿霉素异环磷酰胺化疗方案新辅助治疗骨肉瘤的剂量探索[J].临床肿瘤学杂志,2014,4(4):354-357. [7]胡斌.几种抗肿瘤药物作用于人骨肉瘤裸鼠动物模型的实验研究[D].南京大学,2014. [8]冯和林,郑丽华,赵亚恒,等.洛铂对骨肉瘤MG-63细胞增殖、凋亡的影响及其机制[J].肿瘤防治研究, 2014,41(5):358-362. [9]王旭杰,冯卫华,于春鹏,等.介入联合含洛铂方案治疗原发性肝癌的效果观察[J].齐鲁医学杂志,2015,9(3):280-283. [10]徐轲,张妍蓓,张晶晶.含洛铂化疗方案治疗小细胞肺癌疗效和安全性的系统分析[J].安徽医药,2015,19(11):2187-2191. [11]刘德林,孙蔚莉,武渊,等.含洛铂的联合方案治疗晚期乳腺癌的临床观察[J].临床肿瘤学杂志,2013,18(2):129-132. [12]王辉.孙桂芝治疗骨肉瘤经验[J].世界中医药,2012,07(1):21-22. [13]邹建中,陈文直,廖翠蓉,等.高强度聚焦超声治疗骨肉瘤的声像图表现[J].中华超声影像学杂志,2000,9(11):695-696. [14]张葆青,杨伟毅，石宇雄，等.健脾补肾法治疗骨肉瘤化疗后白细胞减少症17例[J].陕西中医,2007,29(7):41-43. [15]夏时霖,王明,张伟,等.不同化疗方案治疗骨肉瘤的临床观察[J].中国南浔外科杂志,2013,11(12): 72-73. [16]潘立明,李力钧,蔡阳,等.甲氨蝶呤联合顺铂治疗骨肉瘤的临床研究[J].临床肿瘤学,2016,11(1):11-14. [17]邱裕生,胡东岳.动脉灌注灭活再植和体内切刮灭活治疗骨肉瘤的近期疗效观察[J].中华骨科杂志,2013,4(11):649-652.

相似文献/References:

[1]屈欣然.DCE-MRI对局部进展期乳腺癌新辅助化疗的临床指导价值研究[J].医学信息,2018,31(04):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
　QU Xin-ran.Clinical Value of DCE-MRI in Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer[J].Journal of Medical Information,2018,31(21):34.[doi:10.3969/j.issn.1006-1959.2018.04.012]
[2]王文重,伊 扬,董晓昕,等.食管癌患者新辅助化疗前后生理指标变化及意义[J].医学信息,2022,35(09):116.[doi:10.3969/j.issn.1006-1959.2022.09.029]
　WANG Wen-zhong,YI Yang,DONG Xiao-xin,et al.Changes and Significance of Physiological Indexes in Esophageal Cancer Patients Before and After Neoadjuvant Chemotherapy[J].Journal of Medical Information,2022,35(21):116.[doi:10.3969/j.issn.1006-1959.2022.09.029]
[3]张 虎,张 涛,徐 芳,等.MRI在乳腺癌诊治中的研究进展[J].医学信息,2022,35(10):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
　ZHANG Hu,ZHANG Tao,XU Fang,et al.Research Progress of MRI in Diagnosis and Treatment of Breast Cancer[J].Journal of Medical Information,2022,35(21):62.[doi:10.3969/j.issn.1006-1959.2022.10.015]
[4]王绥能,梁贤文,孙 光,等.伊立替康新辅助化疗在进展期胃癌的临床意义[J].医学信息,2018,31(24):164.[doi:10.3969/j.issn.1006-1959.2018.24.050]
　WANG Sui-neng,LIANG Xian-wen,SUN Guang,et al.Clinical Significance of Irinotecan Neoadjuvant Chemotherapy in Advanced Gastric Carcinoma[J].Journal of Medical Information,2018,31(21):164.[doi:10.3969/j.issn.1006-1959.2018.24.050]
[5]黄 雨,楼浩男,涂 刚.Luminal B型乳腺癌TEC新辅助化疗疗效及影响因素分析[J].医学信息,2019,32(04):104.[doi:10.3969/j.issn.1006-1959.2019.04.033]
　HUANG Yu,LOU Hao-nan,TU Gang.Analysis of the Efficacy and Influencing Factors of Neoadjuvant Chemotherapy for Luminal B Breast Cancer[J].Journal of Medical Information,2019,32(21):104.[doi:10.3969/j.issn.1006-1959.2019.04.033]
[6]李 博,李春晓.新辅助化疗在宫颈癌治疗中的应用[J].医学信息,2019,32(15):106.[doi:10.3969/j.issn.1006-1959.2019.15.034]
　LI Bo,LI Chun-xiao.Application of Neoadjuvant Chemotherapy in the Treatment of Cervical Cancer[J].Journal of Medical Information,2019,32(21):106.[doi:10.3969/j.issn.1006-1959.2019.15.034]
[7]张伟娜,黄晓华.多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效评价[J].医学信息,2019,32(08):154.[doi:10.3969/j.issn.1006-1959.2019.08.047]
　ZHANG Wei-na,HUANG Xiao-hua.Clinical Evaluation of Docetaxel Combined with Lobaplatin in the Treatment of Patients with Advanced Ovarian Cancer[J].Journal of Medical Information,2019,32(21):154.[doi:10.3969/j.issn.1006-1959.2019.08.047]
[8]关利平,李建文.凝血相关指标与乳腺癌新辅助化疗疗效预测的相关性研究[J].医学信息,2022,35(16):159.[doi:10.3969/j.issn.1006-1959.2022.16.041]
　GUAN Li-ping,LI Jian-wen.Study on Correlation Between Coagulation- related Indexes and Efficacy Prediction of Neoadjuvant Chemotherapy for Breast Cancer[J].Journal of Medical Information,2022,35(21):159.[doi:10.3969/j.issn.1006-1959.2022.16.041]
[9]任勇军,闵旭立,徐 浩,等.洛铂联合表柔比星化疗栓塞治疗原发性肝细胞癌的疗效[J].医学信息,2019,32(24):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
　REN Yong-jun,MIN Xu-li,XU Hao,et al.Efficacy of Loplatin Combined with Epirubicin Chemotherapy and Embolization for Primary Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(21):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
[10]付大鹏.多西他赛联合表柔比星新辅助化疗治疗乳腺癌的效果[J].医学信息,2020,33(05):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]
　FU Da-peng.Evaluation of Docetaxel Combined with Epirubicin Neoadjuvant Chemotherapy for Breast Cancer[J].Journal of Medical Information,2020,33(21):149.[doi:10.3969/j.issn.1006-1959.2020.04.048]

更新日期/Last Update: 2018-11-20